Immunotherapy Program at Northside(update April 2022)


Northside Hospital Cancer Institute is a nationally recognized treatment center for leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, and blood and marrow transplant. Our Immunotherapy Program is a CAR T-cell Authorized treatment center for the following types of hematological malignancies:

Non-Hodgkin’s Lymphoma:

BREYANZI®
Relapsed/Refractory (R/R) Large B-Cell Lymphoma including:

  • Diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from indolent lymphoma
  • High-grade B-cell lymphoma
  • Primary mediastinal large B-cell lymphoma
  • Follicular lymphoma grade 3B

Adult patients (18+ years)
Must have received two (2) or more lines of systemic therapy

TECARTUS®
Relapsed/Refractory (R/R) Mantle Cell Lymphoma

Adult patients (18+ years)
After first line therapy

YESCARTA®
Relapsed/Refractory Large B-cell lymphoma: First Line Salvage Therapy

Adult patients (18+ years)

  • Refractory to first-line chemoimmunotherapy or relapse within 12 months of first-line
  • chemoimmunotherapy

Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma including:

  • Diffuse large B-cell lymphoma not otherwise specified
  • DLBCL arising from follicular lymphoma
  • High-grade B-cell lymphoma
  • Primary mediastinal large B-cell lymphoma

Relapsed/Refractory (R/R) Follicular Lymphoma

Adult patients (18+ years)

  • After two (2) or more lines of systemic therapy

KYMRIAH®
Relapsed/Refractory (R/R) Large B-Cell Lymphoma including:

  • Diffuse large B-cell lymphoma not otherwise specified
  • DLBCL arising from follicular lymphoma
  • High-grade B-cell lymphoma
  • Adult patients (18+ years)
  • After two (2) or more lines of systemic therapy

Multiple Myeloma:

ABECMA®
Relapsed/Refractory (R/R) Multiple Myeloma*

  • After four (4) or more prior lines of therapy including:
    • an immunomodulatory agent
    • a proteasome inhibitor
    • an anti-CD-38 monoclonal antibody

* Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to determine CAR-T eligibility.

Coming Soon

CARVYKTI®
Relapsed/Refractory (R/R) Multiple Myeloma*

  • After four (4) or more prior lines of therapy including:
    • an immunomodulatory agent
    • a proteasome inhibitor
    • an anti-CD-38 monoclonal antibody

* Newly diagnosed high-risk MM patients (R-ISS III) should be referred soon after initial diagnosis to  determine CAR-T eligibility.

Acute Lymphoblastic Leukemia (ALL):

TECARTUS®
Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Adult Patients (18+ Years)

KYMRIAH®
B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Patients ≤ 25 years
ALL is refractory or in a second or later relapse

CAR T-cell clinical research trials are also available to patients.

Our program meets the rigorous requirements of each manufacturer, in addition to meeting all accreditation standards through the Foundation for the Accreditation of Cellular Therapy (FACT).

The program has an efficient CAR T-cell referral and financial approval process. After treatment and follow up care is completed, patients will return to their primary oncologist.

Please visit immunotherapy clinical trials for a listing of leukemia, relapsed refractory multiple myeloma, diffuse large B-cell lymphoma and other various disease specific immunotherapy trials.